Mariette X, Seror R, Quartuccio L et al.
Université Paris-Sud, Paris, France.
Ann Rheum Dis 2013 Dec 17; Epub ahead of print.
Gerard Espinosa’s review: Belimumab, an inhibitor of B lymphocyte stimulator (BLyS), has been shown to be effective in patients with systemic lupus erythematosus (SLE) and has been approved in the US and Europe for the treatment of this disease. There is evidence for the role of BLyS in the pathogenesis of autoimmune diseases, through promotion of B cell maturation and antibody response. In fact, high serum levels of BLyS have been described in patients with SLE and primary Sjögren’s syndrome (pSS; Ann Rheum Dis 2003;62:168–71). Based on these data, the current authors performed the first study to evaluate the efficacy and safety of belimumab in patients with pSS.